Vor Bio's Board of Directors offers expert global biotechnology experience and perspectives

Robert Ang, MBBS, MBA brings experience as a senior biotech executive and is formerly a physician, venture capitalist, and strategy consultant. Prior to Vor Bio, Robert was Chief Business Officer at Neon Therapeutics, serving as part of the early team that established the company prior to its Series A investment through IPO. Before Neon, he served as Senior Vice President of Business Development at Bavarian Nordic, where he was primarily responsible for conducting a $975 million transaction with Bristol-Myers Squibb for PROSTVAC, a Phase 3 immuno-oncology asset, and served as Head of Business Development and Medical Affairs for Cadence Pharmaceuticals. Robert also worked at Frazier Healthcare Ventures, a leading life sciences venture capital firm, where he was involved in several pharmaceutical and biotechnology investments including Cadence Pharmaceuticals (purchased by Mallinckrodt), Incline Therapeutics (purchased by The Medicines Company), Alnara Pharmaceuticals (purchased by Eli Lilly), and Collegium Pharmaceuticals. Robert also has strategy consulting experience at the Boston Consulting Group and has general surgical training. He holds an MBBS (Doctor of Medicine) from the University of Western Australia and an MBA with honors from Columbia Business School. Robert serves as the Board Chair of Enara Bio, a UK-based biotechnology company focused on non-classical HLA targets for immuno-oncology approaches. He is also a member of the Executive Committee of the Board of Directors of the Alliance for Regenerative Medicine (ARM), the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies.

Daniella Beckman has deep financial and operational experience across the biotechnology industry, having worked with both private and publicly traded companies throughout her career. At Tango Therapeutics, Daniella oversees finance, investor relations, and business development. Prior to joining Tango, she was a consultant to early-stage biotechnology companies, leading financial activities and building companies’ financial infrastructures. She also served as Interim Chief Financial Officer for Neon Therapeutics. Previously, Daniella was Chief Financial Officer of Idenix Pharmaceuticals, responsible for finance, investor relations, and IT until it was acquired by Merck in 2014. Earlier in her career, she held various finance positions at Coley Pharmaceuticals, Biogen Idec, and PricewaterhouseCoopers (PwC). Daniella received her BA in business administration and accounting from Boston University. In addition to Vor Bio, she also serves on the Board of Directors of Blueprint Medicines.

David Lubner is a senior finance executive with more than 25 years of experience in the life sciences industry. David served as Executive Vice President and Chief Financial Officer of Ra Pharma until May 2020 following its acquisition by UCB. Prior to Ra Pharma, he was Senior Vice President and Chief Financial Officer of Tetraphase Pharmaceuticals and was previously Chief Financial Officer of PharMetrics Inc., a leading patient-based pharmacy and medical claims data informatics company. He was also Chief Financial Officer at ProScript, where Velcade® (bortezomib), a therapy widely used for the treatment of the blood cancer multiple myeloma, was discovered. David serves on the Board of Directors of Dyne Therapeutics, Therapeutics Acquisition Corp. (Nasdaq: TXAC), Gemini Therapeutics, and Ichnos Sciences. A Certified Public Accountant, Mr. Lubner received his BS in business administration from Northeastern University and an MS in taxation from Bentley University.

Bill Lundberg, MD is a medical oncologist with more than two decades of experience managing and leading biotechnology research and development. Bill is President and CEO at Merus, a clinical-stage oncology company developing innovative, full-length multispecific antibodies. Prior to joining Merus, he served as Chief Scientific Officer at CRISPR Therapeutics, where he was responsible for establishing and growing research and development in the United States and oversaw CRISPR’s first CRISPR-based product from inception to regulatory filing for clinical trials. Bill was previously Director and Chief Medical Officer of Taligen Therapeutics and Vice President and Head of Translational Medicine at Alexion Pharmaceuticals, where he oversaw R&D from discovery through early clinical development. Prior to this, he held roles of increasing responsibility in drug development and medical affairs at Xanthus (acquired by Antisoma), Wyeth (now Pfizer), and Genzyme. Bill received an MD from Stanford University School of Medicine, an MBA from Isenberg School of Management and a BS from Massachusetts Institute of Technology. He completed postdoctoral training at the Whitehead Institute/MIT and clinical training in medicine and medical oncology from Harvard and the Dana-Farber Cancer Institute.

Matt Patterson is a biotechnology executive with nearly 30 years of experience in the research, development, and commercialization of innovative therapeutics and has held positions of senior management in both private and public biotechnology companies. Matt co-founded Audentes Therapeutics and served as Chief Executive Officer from the Company’s inception in November 2012 until its acquisition by Astellas Pharma Inc. in January 2020. He was also Chairman of the Board of Directors and formerly served as President until May 2018. Previously, Matt worked for Genzyme Corporation, BioMarin Pharmaceutical, and Amicus Therapeutics. Prior to Audentes he was an Entrepreneur-In-Residence with OrbiMed.

Matt is a member of the Board of Directors of Homology Medicines, Inc., Inc., Remix Therapeutics, Inc., and 5:01 Acquisition Corporation. He also served as a member of the Board of Directors of the Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the gene and cell therapy and broader regenerative medicine sector, from 2015-2021, and was Chairman in 2019 and 2020. Matt received his bachelor’s degree in biochemistry from Bowdoin College.

Josh Resnick, MD is a Managing Director at RA Capital Management. Josh’s primary responsibility at RA Capital is to lead early-stage private investments and oversee the creation of new companies developing drugs, medical devices, diagnostics, and research tools. He has more than 15 years of experience in investing, company formation, and company leadership across all stages of drug development, from discovery through commercialization. He was previously Co-Lead of SV Health Investors’ U.S. biotech practice where he was responsible for SV’s U.S. venture creation activities, including its incubator, Brahma Discovery. Before SV, Josh was President and Managing Partner at MRL Ventures Fund, the early-stage therapeutics-focused corporate venture fund within Merck & Co. Prior to MRL Ventures, he was a Venture Partner with Atlas Venture and a Partner at Prism Venture Partners, focusing on company formation and seed and Series A investing. Josh is a faculty member at Harvard Medical School and an attending physician in the Department of Emergency Medicine at Brigham and Women’s Hospital. He holds a BA in chemistry from Williams College, an MD from the University of Pennsylvania School of Medicine, and an MBA from the Wharton School of Business.